Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 41Lymphoid 33Myeloid 14Plasma cell 5Thoracic 2Sarcoma 1Other 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1486Lymphoma, T-Cell, Cutaneous 313Skin Neoplasms 268Keratosis, Actinic 249Mycosis Fungoides 224Sezary Syndrome 216Lymphoma, Non-Hodgkin 206Leukemia, Lymphocytic, Chronic, B-Cell 200Lymphoma, Large B-Cell, Diffuse 198Lymphoma, Follicular 196Neoplasms 194Precursor Cell Lymphoblastic Leukemia-Lymphoma 192Lymphoma, B-Cell, Marginal Zone 192Lymphoma, Mantle-Cell 191Hodgkin Disease 191Carcinoma, Basal Cell 190Breast Neoplasms 185Burkitt Lymphoma 184Lymphoma 182Lymphoma, Large-Cell, Immunoblastic 177Carcinoma, Non-Small-Cell Lung 150Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 140Lymphoma, Large-Cell, Anaplastic 137Multiple Myeloma 133Carcinoma, Renal Cell 128Immunoblastic Lymphadenopathy 126Uveal Melanoma 125Neoplasm Metastasis 120Leukemia, Myeloid, Acute 113Waldenstrom Macroglobulinemia 103

Interventions

Rituximab 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bronchiolitis Obliterans Syndrome × Dermatologic × Clear all
NCT01994382 2022-04-05

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Alexion Pharmaceuticals, Inc.

Phase 1/2 Completed
260 enrolled 33 charts
DermatologicLymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡